Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADX-629 in moderate COVID-19
NCT04847544Phase 2Completed
- Sponsor
- Aldeyra Therapeutics
- Start
- Mar 2021
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing ADX-629 with Placebo (2 arms). Primary endpoint: Number of Subjects With Serious Adverse Events at 28 days. Started Mar 2021; status: completed.
02
Drugs
acloproxalap
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04847544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04847544.